The influence of depression and neuroinflammation on the progression of mild cognitive impairment to dementia: PET imaging of amyloid deposition and microglia activatio

Completed

Conditions: late onset depression
Mild cognitive impairment
10042258
10012272

Registration Number: NL-OMON32861

Lead Sponsor: niversitair Medisch Centrum Groningen

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Completed

Sex: Not specified

Target Recruitment: 48

Inclusion Criteria

• Informed consent
• Aged between 50-80 years
• Assigned by physician as competent to participate in the study
• Inclusion groups:
o Fulfilling the criteria for healthy volunteers
o Fulfilling the criteria for late onset depression
o Fulfilling the criteria for MCI
o Fulfilling the criteria for both late onset depression and MCI

Exclusion Criteria

• History of major psychiatric disorders such as schizophrenia and bipolar disorder and previous unipolar depression
• History of head trauma
• Ischemic cerebrovascular disease, determined by MRI
• Major medical illnesses such as coronary heart disease, diabetes and cancer
• Chronic inflammatory disease such as rheumatoid arthritis, osteoarthritis, chronic obstructive pulmonary disease, psoriasis, etc.
• Use of anti-inflammatory medication such as non-steroidal anti-inflammatory drugs (NSAID) and corticosteroids during a week before PET scan
• The use benzodiazepines a week before the PET scan
• The use of statins, acetylcholinesterase inhibitors, warfarin and digoxin
• History of substance abuse such as alcohol and nicotine (smoking) within the last 6 months
• Presence of dementia
• Any patients with MRI contradictions such as metal implantations and pacemakers
• Malnutrition (vitamin deficiency) or obesity (BMI > 30)

Study & Design

Study Type: Observational invasive

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Quantification of alterations of brain beta-amyloid and activated microglia on<br /><br>the progress of dementia in patients with mild cognitive impairment and late<br /><br>onset depression determined with PET.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>• Plasma pro-inflammatory proteins as well as brain derived neurotrophic factor.<br /><br>• Cognition.<br /><br>• Alterations in brain volume </p><br>